Abstract
The multitargeted tyrosine kinase inhibitor lenvatinib shows promising efficiency and overcomes resistance in FGFR2-driven cholangiocarcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have